$MO

AbbVie (ABBV) lowered its 2026 adjusted EPS guidance to $13.76-$13.96 due to $1.25B in expenses. Altria (MO) offers a 6.2% yield vs. AbbVie's 2.6%. AbbVie's dividend growth is faster but uses more free cash flow. Altria's EPS growth outlook is 3.5%-5.5% for 2026. Both companies face different growth and dividend sustainability challenges.

Altria Group (NYSE:MO) reported Q2 2026 net revenue of $6.11B, flat YoY, with adjusted EPS up 2.8% to $1.48. Full-year EPS guidance is $5.61-$5.72, up 3.5-5.5%. The company faces challenges from declining cigarette sales and slow e-vapor growth. Its forward P/E is 11.9, with an 8.4% earnings yield, reflecting risks like regulation and competition.

Five large-cap companies—Altria, AT&T, Enbridge, Pfizer, and Verizon—offer dividends of 5% or more. Verizon and Altria show strong yield and growth, while others face challenges. Altria raised its dividend by 4.7%, and Verizon improved its guidance. Enbridge's payout is affected by currency fluctuations, and Pfizer's dividend remains flat. AT&T has the lowest yield but strong cash flow and buybacks. Investors should watch for dividend changes and operational updates.

A U.S. judge stayed litigation by Altria's Helix and NJOY against the FDA's 2021 PMTA rule, pending FDA's reassessment. The FDA plans to evaluate and potentially replace the current regulatory framework. The stay was jointly requested by the plaintiffs and the FDA, with a status report required every 45 days. The case challenges the FDA's compliance with the 180-day review period for PMTAs, but the stay does not rule on the merits of the claims.

Altria extended its $3.0 billion revolving credit facility to 2030, with JPMorgan and Citibank as agents. The move aims to preserve liquidity and financial flexibility.

ALTRIA GROUP, INC. (MO) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. Effective October 7, 2026, Altria Group, Inc. (“Altria”) entered into an extension agreement (the “2026 Extension Agreement”) to amend its $3.0 billion senior unsecured 5-year revolving credit agreement, dated as of October 2

AVM, Helix Innovations, and NJOY (subsidiaries of Altria Group) seek to intervene in a lawsuit challenging the FDA's May 2026 enforcement guidance for e-cigarette and nicotine pouch products. The FDA's guidance lowers enforcement priorities for certain unauthorized products with pending PMTAs. The plaintiffs, including health groups, argue the guidance violates federal tobacco law and administrative procedures.

Tradewinds Universal (TRWD) is expanding its adult hospitality business through acquisitions and licensing, with a focus on technology and services. The company signed its first U.S. licensing agreement, targeting over 100 venues. RCI Hospitality (RICK) reported strong sales growth in its Bombshells chain, while Anheuser-Busch (BUD) saw growth in non-alcoholic beer and premium brands. Altria (MO) reported steady earnings, with nicotine pouches gaining market share.

Analysts from Barclays, B of A Securities, Citigroup, Wells Fargo, TD Cowen, and Evercore ISI updated ratings and price targets for Altria Group (MO), Clorox (CLX), and General Mills (GIS), all high-dividend consumer staples stocks. MO's dividend yield is 6.59%, CLX's is 6.22%, and GIS's is 7.62%. Recent news includes manufacturing agreements, earnings reports, and executive changes.

Altria (MO) faces challenges with falling cigarette volumes, shrinking market share, and a high dividend payout ratio. Its smoke-free strategy is struggling, and its balance sheet shows negative equity. Despite a 6.6% yield, concerns arise about dividend sustainability and business decline. Philip Morris (PM) is cited as a better-performing peer.